Diabetes Health in the News Podcast: Jardiance Reduces Cardiovascular Risk for Type 2 Diabetes

Click here to listen to the audio recording of Diabetes Health in News Podcast. 

Boehringer Ingelheim and Eli Lilly and Company announced their primary results for the EMPA-REG outcome trial. The study showed that Jardiance® (empagliflozin), significantly reduces  the risk  for cardiovascular death,  by 14% for patients living with  type 2 diabetes, who are at a  higher risk for a cardiovascular event.

The trial also found:

  • There was a 38% reduction in cardiovascular death, with no significant difference, in the risk of non-fatal heart attack or non-fatal strokes
  • Treatment with Jardiance  also resulted in a 32%  lower mortality risk and a 35% reduction in hospitalization for heart failure

The results of the trial were presented  at the 51st European Association for the Study of Diabetes, Annual Meeting in Stockholm, Sweden, and was also published in the New England Journal of Medicine.

Leave a Reply

Your email address will not be published. Required fields are marked *